However, Belimumab exhibits low efficacy for SLE treatment, we reasoned that it cannot totally blocks noncanonical NF-κB activation, since non-neutralized CD40L and TACI are also two major inducers for noncanonical pathway. This evidence concerns the gene CD40LG and systemic lupus erythematosus.